The FDA's approval of Ubrelvy is the next step in a bigger trend of new migraine medications
The FDA approved Ubrelvy, Allergan’s new oral medication for migraine treatment, on Monday, December 23. The news isn’t only good for Allergan— this drug is one in a larger migraine medication revolution that has been occurring over the past several years.
. In clinical trials, Ubrelvy relieved migraine-related pain for a majority of migraine patients, often within two hours. When the first three CGRP migraine medications hit the market in 2018, it was a landmark moment for migraine treatment. The medications are Aimovig from Novartis and Amgen, Emgality, from Eli Lilly, and Teva’s Ajovy.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA Approves New Type of Drug to Treat MigrainesThe FDA approved a new treatment option for migraine patients who cannot get relief from existing medications once an attack strikes.
Consulte Mais informação »
1st monthly HIV drug doesn't receive FDA approvalOn Saturday, the Food and Drug Administrations declined the approval of the much anticipated Cabenuva, the first long acting HIV drug.
Consulte Mais informação »
Allergan's acute migraine treatment wins U.S. FDA approvalThe U.S. Food and Drug Administration said on Monday it had approved Allergan Pl...
Consulte Mais informação »
FDA Approves New Type of Drug to Treat MigrainesThe FDA approved a new treatment option for migraine patients who cannot get relief from existing medications once an attack strikes.
Consulte Mais informação »
Allergan's acute migraine treatment wins U.S. FDA approvalThe U.S. Food and Drug Administration said on Monday it had approved Allergan Pl...
Consulte Mais informação »
1st monthly HIV drug doesn't receive FDA approvalOn Saturday, the Food and Drug Administrations declined the approval of the much anticipated Cabenuva, the first long acting HIV drug.
Consulte Mais informação »